Immunoprecise Stock Price, News & Analysis

ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) has announced a significant commercial collaboration with Eurofins Discovery, enhancing their therapeutic discovery capabilities. This partnership combines Eurofins' in vitro pharmacology services with ImmunoPrecise’s in vivo discovery technologies to support drug development across various indications. The collaboration aims to provide scientists with advanced solutions, improving access to antibody discovery and supporting Eurofins' biotherapeutics strategy. This innovative alliance seeks to optimize the processes from target validation to preclinical development.

ImmunoPrecise Antibodies (IPA) announced further results from the in vivo efficacy study of TATX-03a PolyTope™ Therapy for SARS-CoV-2, showing reduced inflammation in bronchitis and tracheitis. The study confirmed that treatment with TATX-03a diminished inflammation severity compared to controls, enhancing the therapy's potential for COVID prevention and treatment. Concurrently, optimization efforts on antibody components aim to enhance clinical suitability and manufacturing yields. IPA plans to submit an IND for TATX-03 to commence human studies.

ImmunoPrecise Antibodies (IPA) announced the presentation of in vitro results for TATX-21, a novel antibody targeting Atherosclerosis Cardiovascular Disease (ACVD), at the 2021 BIO International Convention. The lead candidate pool, developed using the B cell Select™ technology, consists of 25 unique antibodies aimed at preventing low-density lipids (LDL) uptake. IPA aims to explore TATX-21's potential in treating both ACVD and diabetic retinopathy. The company continues to advance its internal therapeutics pipeline, focusing on novel treatment approaches.

ImmunoPrecise Antibodies Ltd. (IPA) announced that Chief Scientific Officer Dr. Yasmina Abdiche will resign effective July 1, 2021, to pursue other opportunities. Dr. Ilse Roodink, currently Scientific Director and Global Project Manager for the COVID-19 program, has been appointed as the new Chief Scientific Officer. Dr. Roodink's experience includes leading the SARS-CoV-2 Polytope™ Cocktail program and overseeing contract research projects at IPA's Dutch facility. CEO Dr. Jennifer Bath expressed gratitude for Dr. Abdiche's contributions while highlighting Dr. Roodink's leadership in advancing the company's goals.

ImmunoPrecise Antibodies Ltd. (IPA) has announced Dr. Dion Neame's appointment to its Strategic Advisory Board at a crucial growth phase for the company. With over 15 years in pharma, Dr. Neame brings expertise in clinical medicine, vaccine strategies, and stakeholder engagement. His role will support IPA's strategic partnerships and scientific initiatives, enhancing the company's capabilities in therapeutic antibody discovery. Dr. Neame's experience includes significant contributions to vaccination programs across Canada, positioning him to drive IPA's innovative approaches in combating infectious diseases.

ImmunoPrecise Antibodies Ltd. (IPA) has completed a preclinical study showcasing the efficacy of its four monoclonal antibody cocktail, TATX-03b, against SARS-CoV-2. This study highlights strong therapeutic efficacy and synergy between the antibodies, particularly effective against new variants. Key findings include 100% viral suppression in infected hamsters and confirmed efficacy against recent variants. IPA is also preparing for clinical manufacturing and has contracted ChemPartner Biologics for production support.

ImmunoPrecise Antibodies Ltd. (IPA) announced the appointment of LifeSci Advisors as its investor relations agent. President and CEO Jennifer Bath expressed optimism about this partnership, emphasizing the importance of communication as the company evolves. LifeSci Advisors boasts a global presence and extensive client base, providing comprehensive solutions for investor outreach and visibility. IPA focuses on therapeutic antibody discovery and aims to innovate traditional product development models while enhancing client engagement.

ImmunoPrecise Antibodies Ltd. (IPA) announced that its subsidiary Talem Therapeutics has progressed its therapeutic antibody panel, TATX-112, into formal lead candidate characterization. TATX-112 aims to target a protein receptor overexpressed in various cancers, potentially increasing treatment specificity and reducing side effects. Additionally, the antibodies may offer therapeutic options for neurodegenerative diseases by enhancing receptor signaling. Talem is exploiting its proprietary B cell Select™ and DeepDisplay™ platforms for antibody discovery across various disease areas.

ImmunoPrecise Antibodies Ltd. (IPA) announced the identification of antibody 23-H7, which shows strong protective effects against SARS-CoV-2 in preclinical studies. This antibody disrupts the RBD-ACE2 interaction but is less susceptible to mutations than current therapies. In vivo studies indicated undetectable virus replication in most treated animals. IPA's PolyTope platform allows for combination therapies to enhance viral clearance, reducing the risk of escape mutations. This discovery underscores IPA's commitment to innovative antibody development and effective COVID-19 treatments.